Post-Marketing Surveillance (PMS) Protocol of REKOVELLE Pre-Filled Pen (Follitropin Delta)

NCT ID: NCT04654039

Last Updated: 2025-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

728 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-26

Study Completion Date

2023-10-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This post-marketing surveillance study was conducted in accordance with the regulations for re-examination of domestic new drugs (Standard for Re-Examination of New Drugs: Ministry of Food and Drug Safety \[MFDS\]: Notification No. 2017-95, 21 Nov, 2017).

It was important to monitor the pattern of drug use in general practice for a long term after marketing authorization, and to investigate and identify potential new adverse events (AEs) and their onset status that were not observed during the drug development phases and any potential factors that affect safety and effectiveness of the new drug.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility, Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment of Infertility

Non intervention

Other: Non intervention

Intervention Type OTHER

Non intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Other: Non intervention

Non intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who were prescribed with REKOVELLE (follitropin delta) for the first time according to the approved administration method and dose
* Participants who have consented to personal information use

Exclusion Criteria

* Participants who are prohibited from use according to the special warnings and precautions for use of REKOVELLE (follitropin delta)
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ferring Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Global Clinical Compliance

Role: STUDY_DIRECTOR

Ferring Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pyeongchon Maria, 8/9F, Olympic Sports Center120, Dongan-ro, Dongan-gu

Anyang, , South Korea

Site Status

Dream-I clinic, 45-17, Huimang-ro 46beon-gil, Baebang-eup

Asan, , South Korea

Site Status

Centum Eroom Woman Clinic, 10F, Centum Tower Medical, 20, Centum-2-ro, Haeundae-gu

Busan, , South Korea

Site Status

Eroom women's clinic, 25, Seomyeon-ro, Busanjin-gu

Busan, , South Korea

Site Status

Seoul Women's Hospital, 7, Munjeong-ro, Seo-gu

Daejeon, , South Korea

Site Status

Creation And Love Women's Hospital, 957, Mujin-daero, Seo-gu

Gwangju, , South Korea

Site Status

Mirae and Heemang Women's Hospital, 7F, Dana Medical Center, 68, Jukbong-daero, Seo-gu

Gwangju, , South Korea

Site Status

Design Hospital

Jeonju, , South Korea

Site Status

Trinium Woman's Hospital, 1834, MainTower, Hannuridae-ro

Sejong, , South Korea

Site Status

CHA university Bundang medical center, 59, Yatap-ro, Bundang-gu

Seongnam, , South Korea

Site Status

Seoul Nation University Bundang Hospital, 82, Gumi-ro 173beon-gil, Bundang-gu

Seongnam, , South Korea

Site Status

M Fertility Center, 12F, 407, Teheran-ro, Gangnam-gu

Seoul, , South Korea

Site Status

MariaS (Sangbong), 267, Mangu-ro, Jungnang-gu

Seoul, , South Korea

Site Status

Mizmedi Hospital, 295, Gangseo-ro, Gangseo-gu

Seoul, , South Korea

Site Status

Seoul Maria Fertility Hospital, 20, Cheonho-daero, Dongdaemun-gu

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

000385

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Personalized Insemination Treatment Study
NCT03830723 COMPLETED PHASE2
Rekovelle PK Trial in Chinese Women
NCT04150861 COMPLETED PHASE1